For the Inventor, By the Inventor

Enter inventor name

Kensington, MD, United States of America

Dan L Longo

USPTO Granted Patents = 13 (Patent Applications = 2)

EPO Patents = 1

Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 140(Granted Patents)

Company Filing History:

The United States of America As Represented by the Department of Health

University of Minnesota

The United States of America, As Represented by the Secretary, Department of Health and Human Services

4. 1 out of 451

Immunex Corporation

Biomira USA Inc.

The United States of America As Represented by the Secretary, Department

Biormia USA Inc.

8. 1 out of 2,202

The United States of America As Represented by the Secretary of

9. 1 out of 3,687

Johns Hopkins University

where one patent can have more than one assignee

Years Active: 1994-2018

Loading Chart...

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10077296 - Methods and compositions for the treatment and prevention of cancer (2018-09-18),

2. 9086403 - Methods of screening for cell proliferation or neoplastic disorders (2015-07-21),

3. 8258278 - Methods and compositions for the treatment and prevention of cancer (2012-09-04),

4. 5965366 - Methods of identifying patients having an altered immune status (1999-10-12),

5. 5889143 - Evaluation and treatment of patients with progressive immunosuppression (1999-03-30),

6. 5861158 - Method and composition for transfer of active tumor-specific (1999-01-19),

7. 5725855 - Method of treating tumors with CD8.sup.+ -depleted or CD4.sup.+ T cell (1998-03-10),

8. 5674492 - Method of preventing or treating disease characterized by neoplastic (1997-10-07),

9. 5658744 - Methods of identifying patients having an altered immune status (1997-08-19),

10. 5583002 - Evaluation and treatment of patients with progressive immunosuppression (1996-12-10),

11. 5556763 - Evaluation and treatment of patients with progressive immunosuppression (1996-09-17),

12. 5316763 - Short-term anti-CD3 stimulation of lymphocytes to increase their in vivo (1994-05-31),

13. 5296353 - Evaluation and treatment of patients with progessive immunosuppression (1994-03-22),

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…